Skip to content
AnalystLens

Medpace HoldingsMEDP

Legal name
Medpace Holdings, Inc.
Industry
Services-Commercial Physical & Biological Research
Exchange
Nasdaq

Stock Price $MEDP

Filing record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Change in control8-K · Jun ’17Jun ’17
  2. Leadership change8-K · May ’19May ’19
  3. Leadership change8-K · Jul ’21Jul ’21
  4. Material agreement8-K · Jul ’25Jul ’25
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025
Source: 10-KFY2025

Revenue Trend

Year-over-year comparison from 10-K annual reports

  1. $2.53B
YoY changeLargest recent move+61.5%in FY18Latest +20.0%

Latest bar from 10-KFY2025Click a bar to open its SEC filing

View full history →

Medpace Holdings Financial Overview 2021–2025

Updated Nov 4, 2026

Medpace spent $912.9 milliona on buybacks in FY2025, nearly double its $484.9 million of net income less... no: more than twice its $451.1 million of net income, and still ended the year with $497.0 million in cash and no debt. That is the story. Operating cash flow ran well ahead of earnings, so the company shrank its share count without borrowing a dollar.

The core thesis: Medpace turns rapid revenue growth into cash, then hands that cash back to shareholders. Revenue grew from $1,142.4 million in FY2021 to $2,530.2 millionb in FY2025, while diluted EPS climbed from $4.81 to $15.28. Growth cooled to 11.8% in FY2024 before reaccelerating to 20.0% in FY2025. Backlog reached $3,027.2 million at year-end FY2025, with $1,890.0 million to $1,910.0 million expected to convert to revenue in 2026.

Risks are visible in the numbers. The top ten customers supplied 35.1% of FY2025 revenue, up from 28.9% in FY2024, and 82% came from small biopharma. Net new awards slipped to $2,230.0 millionc in FY2024 from $2,356.7 million. Shareholders' equity also fell below $400 million during the buyback push. On valuation, the stock closed FY2025 at $561.65, or 36.8x earnings, for a market cap of $15.9 billion. That multiple is the price of the compounding.

Recent Developments (Q2 and Q3 2026)

Growth slowed in Q3 2026. Revenue rose 8.5% to $716.0 milliond, after 17.2% growth in Q2 2026. Margins widened, though. Q3 EBITDA hit $172.1 million, a 24.0% margin, and diluted EPS reached $4.84 versus $3.86. Backlog grew to $3,167.2 million, up 5.6%. Management narrowed 2026 revenue guidance to $2.835 billion to $2.855 billion and raised the EPS range to $17.97 to $18.32. Buybacks paused in Q3, and cash rose to $705.3 million. On October 20, 2026, the Board replaced the old authorization with up to $1.0 billion through 2028. Shareholder suits over book-to-bill statements were dismissed without prejudice. Brad Hansman became co-head of operations in June.

Bull case: awards of $873.4 millione and a new $1.0 billion buyback support earnings growth. Bear case: slowing revenue growth is hard to square with 42.8x trailing earnings as of the October 21, 2026 filing date, not today.

What to watch: Q4 revenue growth against the narrowed guidance; pace of buybacks under the new authorization

Recent SEC Filings

  1. 8-KMedpace Holdings 8-K Report, Financial Results (Oct 21, 2026)Medpace Holdings, Inc. reported third quarter 2026 results on October 21, 2026, as furnished under Item 2.02 with the press release attached as Exhibit 99.1. Revenue for the quarter was $716.0 million, up 8.5% from $659.9 million a year earlier, and the backlog conversion rate was 23.8%. Net new business awards were $873.4 million, up 10.6% from $789.6 million. GAAP net income was $137.5 million, or $4.84 per diluted share, versus $111.1 million, or $3.86 per diluted share, in the prior-year quarter. EBITDA was $172.1 million, up 16.0%, with an EBITDA margin of 24.0%. Backlog as of September 30, 2026 was $3,167.2 million, up 5.6%. For the nine months ended September 30, 2026, revenue was $2,129.9 million, up 16.9% on a reported basis, and GAAP net income was $382.7 million, or $13.37 per diluted share. The company forecasts 2026 revenue of $2.835 billion to $2.855 billion, GAAP net income of $514.0 million to $524.0 million, and diluted EPS of $17.97 to $18.32. Guidance excludes any share repurchases made after September 30, 2026. Under Item 8.01, the Board terminated the existing repurchase authorization, which had $527.0 million remaining and was set to expire December 31, 2026, effective October 20, 2026, and approved a new authorization of up to $1.0 billion of common stock through December 31, 2028. Repurchases are to be funded from cash on hand, and the authorization may be modified or terminated at any time. The company reported cash and cash equivalents of $705.3 million at September 30, 2026, and no share repurchases in the third quarter.
  2. 8-KMedpace Holdings 8-K Report, Financial Results (Jul 22, 2026)Medpace Holdings, Inc. reported second quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Revenue was $707.3 million, up 17.2% from $603.3 million a year earlier, and GAAP net income was $121.4 million, or $4.25 per diluted share, versus $90.3 million, or $3.10 per diluted share, in the prior-year quarter. EBITDA was $153.4 million, up 17.6%, with an EBITDA margin of 21.7%. Net new business awards were $795.7 million, up 28.2%, for a net book-to-bill ratio of 1.13x, and backlog as of June 30, 2026 rose 4.9% to $3,014.2 million. For the six months ended June 30, 2026, revenue was $1,413.9 million, up 21.7% on a reported basis, and GAAP net income was $245.2 million, or $8.53 per diluted share. The company ended the quarter with $502.7 million in cash and cash equivalents, generated $162.0 million in operating cash flow in the second quarter, and repurchased 705,616 shares for $294.7 million, leaving $527.0 million under its share repurchase program. The company forecasts full-year 2026 revenue of $2.805 billion to $2.885 billion, representing growth of 10.9% to 14.0% over 2025 revenue of $2.530 billion. It guides to GAAP net income of $494.0 million to $514.0 million, diluted EPS of $17.25 to $17.95, and EBITDA of $618.0 million to $642.0 million. Guidance assumes a tax rate of 19.0% to 19.5% and 28.6 million diluted weighted average shares, and excludes any share repurchases after June 30, 2026. Management will host a conference call on July 23, 2026 at 9:00 a.m. ET.
  3. 8-KMedpace Holdings 8-K Report, Executive Changes (Jun 4, 2026)Medpace Holdings, Inc. (MEDP) filed a Form 8-K under Item 5.02 reporting the appointment of Brad W. Hansman, age 43, to the position of Executive Vice President, Operations, effective June 1, 2026. In this role, Mr. Hansman will perform the functions of the Company's principal operating officer alongside Susan E. Burwig, who holds the title of Executive Vice President, Operations. Mr. Hansman has been with the Company since April 2011. He began in Finance & Accounting, held various Finance roles until July 2015, and since August 2015 has held operations leadership roles including Executive Director, Vice President, and Senior Vice President, overseeing study start-up, logistics, regulatory affairs, and medical writing. Before joining the Company, he worked as an Audit Supervisor at Joseph Decosimo & Company, LLC and as an auditor at Macy's, Inc. He holds a Bachelor of Business Administration in Accounting from Eastern Kentucky University and is a Certified Public Accountant (inactive). The filing states he holds no public company directorships and has no family relationships with any director, director nominee, or executive officer. Compensation disclosed in the filing consists of an annual base salary of $492,250, eligibility for the short-term incentive plan with target cash bonus opportunities described in the Company's April 1, 2026 Proxy Statement, and eligibility for the long-term equity incentive plan at the discretion of the Compensation Committee. He also entered the Company's standard director and officer indemnification agreement.
  4. 8-KMedpace Holdings 8-K Report, Bylaw Amendment (May 19, 2026)At its 2026 Annual Meeting on May 15, 2026, Medpace Holdings, Inc. stockholders approved two amendments to the Restated Certificate of Incorporation: removing supermajority voting requirements and removing the limitation on stockholders calling special meetings. The amendments became effective upon filing with the Delaware Secretary of State on May 18, 2026, and the company filed a Restated Certificate of Incorporation integrating them the same day. The Board approved conforming changes to the bylaws, under which one or more stockholders owning at least 25% of the voting power of outstanding shares may call a special meeting. Requesting stockholders must also meet notice, information, and other requirements, including having continuously owned at least 25% of the voting power for one year. Stockholders also elected five directors to serve until the 2027 Annual Meeting: Brian T. Carley, Femida H. Gwadry-Sridhar, Robert O. Kraft, August J. Troendle, and Dani S. Zander. They ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the advisory vote on named executive officer compensation, with 22,656,335 votes for and 1,737,558 against. In the advisory vote on say-on-pay frequency, the largest share of votes favored one year (23,989,262), and the Board determined that future advisory votes on executive compensation will be held annually. A non-binding stockholder proposal on giving shareholders the ability to call special meetings drew 8,306,071 votes for and 16,081,493 votes against, with 34,664 abstentions. The filing reports these results without describing the proposal's outcome beyond the vote counts.
  5. 8-KMedpace Holdings 8-K Report, Financial Results (Apr 22, 2026)Medpace Holdings, Inc. reported financial results for the three months ended March 31, 2026, in a press release furnished as Exhibit 99.1 to this Form 8-K filed April 22, 2026. Revenue rose 26.5% to $706.6 million from $558.6 million a year earlier. Net new business awards were $618.4 million, up 23.7% from $500.0 million, for a net book-to-bill ratio of 0.88x. Backlog as of March 31, 2026 was $2,929.2 million, up 2.9% from $2,846.0 million. GAAP net income was $123.9 million, or $4.28 per diluted share, compared with $114.6 million, or $3.67 per diluted share, in the prior-year quarter. EBITDA was $149.4 million, up 25.9%, with an EBITDA margin of 21.1%. For full-year 2026, the company forecasts revenue of $2.755 billion to $2.855 billion, GAAP net income of $487.0 million to $511.0 million, EBITDA of $605.0 million to $635.0 million, and diluted EPS of $16.68 to $17.50. The guidance assumes a 19.0% to 20.0% tax rate and 29.2 million diluted weighted average shares, and excludes any share repurchases after March 31, 2026. Cash and cash equivalents were $652.7 million at March 31, 2026, and operating cash flow for the quarter was $151.8 million. The filing also discloses that President Jesse Geiger notified the company on April 21, 2026, of his intent to resign and retire effective May 31, 2026, and that the departure is not the result of any disagreement with the company. Chief Executive Officer August Troendle will reassume the role of President until a successor is appointed.
View all 8-K filings →